Skip to main content
Nanologica logo

Nanologica — Investor Relations & Filings

Ticker · NICA ISIN · SE0005454873 LEI · 54930017L41C7P87LP22 ST Manufacturing
Open in API
Filings indexed 181 across all filing types
Latest filing 2026-02-26 Interim / Quarterly Rep…
Country SE Sweden
Listing ST NICA

About Nanologica

https://nanologica.com/

Nanologica is a life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. The company specializes in nanoporous silica particles for preparative chromatography, a critical step in drug production. Its core product, NLAB Saga®, is a spherical, porous silica media engineered for the large-scale purification of peptide drugs, such as insulin and GLP-1 analogues used to treat diabetes and obesity. The product's high mechanical and chemical stability provides effective purification and a long lifetime, which increases productivity and reduces costs for pharmaceutical manufacturers. Nanologica's mission is to lower the manufacturing costs of these drugs, thereby increasing patient access to life-saving treatments. The company is also developing a broader portfolio of purification media.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'YEAR-END REPORT 2025' for Nanologica AB. It contains comprehensive financial summaries, including net sales, operating profit/loss, cash flow, and balance sheet data for the fourth quarter and the full year 2025. It also includes management commentary (CEO statement) and detailed business updates. Since it provides substantive financial statements and analysis for a period shorter than a full fiscal year (the fourth quarter) and the full year, it is classified as an Interim/Quarterly Report. Q4 2025
2026-02-26 English
KALLELSE TILL EXTRA BOLAGSSTÄMMA I NANOLOGICA AB (PUBL)
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Kallelse till extra bolagsstämma' (Notice of Extraordinary General Meeting) for Nanologica AB. It contains the agenda, proposals for board decisions (such as share issues and amendments to the articles of association), and instructions for shareholders to participate. This document is a classic proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and request their votes on specific resolutions.
2026-01-30 Swedish
NOTICE OF EXTRAORDINARY GENERAL MEETING IN NANOLOGICA AB (PUBL)
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Extraordinary General Meeting' for Nanologica AB. It contains the agenda, voting requirements, and detailed proposals for corporate actions such as amendments to the Articles of Association and various share issuance resolutions. This document is provided to shareholders to inform them of the upcoming meeting and to solicit their votes on the proposed items. According to the filing definitions, materials sent to shareholders to provide information and request votes for meetings are classified as Proxy Solicitation & Information Statement (PSI).
2026-01-30 English
NANOLOGICA GENOMFÖR RIKTADE EMISSIONER OM TOTALT CIRKA 13,7 MSEK SAMT EN FULLT SÄKERSTÄLLD FÖRETRÄDESEMISSION OM CIRKA 82,5 MSEK
Share Issue/Capital Change Classification · 100% confidence The document is a press release from Nanologica AB announcing a series of capital raising activities, including a directed share issue, a rights issue, and a set-off issue (debt-for-equity swap). It details the purpose of the capital (working capital, production, and debt settlement), the terms of the issues, and the involvement of major shareholders and management. This falls under the category of announcements regarding new share issues and capital structure changes.
2026-01-30 Swedish
NANOLOGICA CARRIES OUT DIRECTED SHARE ISSUES OF APPROX. SEK 13.7 MILLION IN TOTAL, AND A FULLY SECURED RIGHTS ISSUE OF APPROX. SEK 82.5 MILLION
Capital/Financing Update Classification · 100% confidence The document is a press release detailing a company's plan to raise capital through a combination of a directed share issue and a rights issue. It outlines the purpose of the funds, the terms of the share issues, the involvement of major shareholders, and the necessity of an Extraordinary General Meeting to approve these actions. This falls under the category of capital and financing updates.
2026-01-30 English
Nanologica AB (publ) förvärvar Ardena Södertälje AB
M&A Activity Classification · 100% confidence The document is a press release from Nanologica AB announcing the acquisition of Ardena Södertälje AB (Syntagon). It details the transaction terms, strategic rationale, financial impact, and future management changes. As this document describes a merger and acquisition (M&A) activity, it falls under the 'M&A Activity' category.
2026-01-29 Swedish

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.